CpG-ODN Class C Mediated Immunostimulation in Rabbit Model of Trypanosoma Evansi Infection

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Jun 4

PMID 26039713

Citations 3

Authors

Parveen Kumar

Rakesh Kumar

Balvinder Kumar Manuja

Harisankar Singha

Anshu Sharma

Nitin Virmani

Suresh Chandra Yadav

Anju Manuja

Affiliations

Soon will be listed here.

Abstract

CpG oligodeoxynucleotides (CpG-ODN) stimulate immune cells from a wide spectrum of mammalian species. Class C CpG-ODN is relatively stable and has the combined immune effects of both A and B classes of CpG-ODN. Trypanosoma evansi produces the state of immuno-suppression in the infected hosts. The current chemotherapeutic agents against this parasite are limited in number and usually associated with severe side effects. The present work aimed to determine the immunostimulatory effects of CpG-ODN class C in T. evansi infected rabbits. Rabbits inoculated with CpG C and challenged with T. evansi resulted in delayed onset of clinical signs with reduced severity in comparison to that of T. evansi infected rabbits. The treatment also enhanced humoral immune responses. Histopathological findings in liver and spleen revealed enhancement of mononuclear cell infiltration and secondary B cell follicles. These results demonstrate that CpG-ODN class C, has immunostimulatory properties in rabbit model of trypanosomosis. The use of booster doses or sustained delivery of CpG-ODN will further elucidate the prolonged CpG-ODN generated immune responses.

Citing Articles

Single-cell transcriptome profiling and the use of AID deficient mice reveal that B cell activation combined with antibody class switch recombination and somatic hypermutation do not benefit the control of experimental trypanosomosis.

Nguyen H, Guevarra R, Magez S, Radwanska M PLoS Pathog. 2021; 17(11):e1010026.

PMID: 34762705 PMC: 8610246. DOI: 10.1371/journal.ppat.1010026.

Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey ().

Nehete P, Williams L, Chitta S, Nehete B, Patel A, Ramani M Front Aging Neurosci. 2020; 12:36.

PMID: 32194391 PMC: 7063459. DOI: 10.3389/fnagi.2020.00036.

Biocompatibility and Targeting Efficiency of Encapsulated Quinapyramine Sulfate-Loaded Chitosan-Mannitol Nanoparticles in a Rabbit Model of Surra.

Manuja A, Kumar B, Kumar R, Chopra M, Dilbaghi N, Kumar S Antimicrob Agents Chemother. 2018; 62(11).

PMID: 30104283 PMC: 6201129. DOI: 10.1128/AAC.00466-18.

References

Frank F, Petray P, Cazorla S, Munoz M, Corral R, Malchiodi E . Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine. 2003; 22(1):77-86. DOI: 10.1016/s0264-410x(03)00541-3. View

Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H . A Toll-like receptor recognizes bacterial DNA. Nature. 2000; 408(6813):740-5. DOI: 10.1038/35047123. View

Weeratna R, McCluskie M, Xu Y, Davis H . CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 2000; 18(17):1755-62. DOI: 10.1016/s0264-410x(99)00526-5. View

Yadav S, Kumar R, Kumar S, Tatu U, Singh R, Gupta A . Identification and characterization of cysteine proteinases of Trypanosoma evansi. Parasitol Res. 2011; 109(3):559-65. DOI: 10.1007/s00436-011-2284-9. View

Davis H, Weeratna R, Waldschmidt T, Tygrett L, Schorr J, Krieg A . CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol. 1998; 160(2):870-6. View

Sudarto M, Tabel H, Haines D . Immunohistochemical demonstration of Trypanosoma evansi in tissues of experimentally infected rats and a naturally infected water buffalo (Bubalus bubalis). J Parasitol. 1990; 76(2):162-7. View

Krieg A . Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006; 5(6):471-84. DOI: 10.1038/nrd2059. View

Elkins K, Stibitz S, Conover J, Klinman D . Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol. 1999; 162(4):2291-8. View

Borst P, Rudenko G . Antigenic variation in African trypanosomes. Science. 1994; 264(5167):1872-3. DOI: 10.1126/science.7516579. View

10.

Gramzinski R, Doolan D, Sedegah M, Davis H, Krieg A, Hoffman S . Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun. 2001; 69(3):1643-9. PMC: 98068. DOI: 10.1128/IAI.69.3.1643-1649.2001. View

11.

Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M . Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004; 34(1):251-62. DOI: 10.1002/eji.200324032. View

12.

Dargantes A, Reid S, Copeman D . Experimental Trypanosoma evansi infection in the goat. I. Clinical signs and clinical pathology. J Comp Pathol. 2005; 133(4):261-6. DOI: 10.1016/j.jcpa.2005.06.001. View

13.

Jurk M, Schulte B, Kritzler A, Noll B, Uhlmann E, Wader T . C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology. 2004; 209(1-2):141-54. DOI: 10.1016/j.imbio.2004.02.006. View

14.

Zhao Q, Temsamani J, Zhou R, Agrawal S . Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997; 7(5):495-502. DOI: 10.1089/oli.1.1997.7.495. View

15.

Manuja A, Kumar P, Kumar R, Kumar B, Singha H, Sharma R . CpG-ODN class C-mediated immunostimulation and its potential against Trypanosoma evansi in equines. Int Immunopharmacol. 2014; 22(2):366-70. DOI: 10.1016/j.intimp.2014.07.016. View

16.

Krieg A . CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002; 20:709-60. DOI: 10.1146/annurev.immunol.20.100301.064842. View

17.

Zhao Q, Yu D, Agrawal S . Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg Med Chem Lett. 2000; 9(24):3453-8. DOI: 10.1016/s0960-894x(99)00635-6. View

18.

Biswas D, Choudhury A, Misra K . Histopathology of Trypanosoma (Trypanozoon) evansi infection in bandicoot rat. I. visceral organs. Exp Parasitol. 2002; 99(3):148-59. DOI: 10.1006/expr.2001.4664. View

19.

SANDS H, Cocuzza A, Hobbs F, Chidester D, Trainor G . Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994; 45(5):932-43. View

20.

Kumar R, Kumar S, Khurana S, Yadav S . Development of an antibody-ELISA for seroprevalence of Trypanosoma evansi in equids of North and North-western regions of India. Vet Parasitol. 2013; 196(3-4):251-7. DOI: 10.1016/j.vetpar.2013.04.018. View